Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in theme_biblio_custom() (line 367 of /home/ajbls/public_html/sites/all/modules/biblio/includes/

Prospective Role of Unani Pharmacopeial Formulation Safoof Hijrul Yahood in Preventing Recurrence of Nephrolithiasis: An Open Labeled Clinical Study

Asian Journal of Biological and Life Sciences,2023,12,1,144-150.
Published:May 2023
Type:Research Article
Author(s) affiliations:

Arjumand Shah1, Huma1, Arsheed Iqbal1, Umar Jahangir3, Kausar Shah1, Sabia1, Arif H Hanga1, Shaista Urooj2,*, TA Rafiqi1

1Research Officer, Regional Research Institute of Unani Medicine, Srinagar, Jammu and Kashmir, INDIA.

2Regional Research Institute of Unani Medicine, New Delhi, INDIA.

3School of Unani Medical Education and Research, Jamia Hamdard, New Delhi, INDIA.


Background: The recurrence of nephrolithiasis has high incidence in northern region of India posing major health problems. Aim and Objectives: To study the efficacy of Unani pharmacopeial formulation Safoof Hajrul Yahood (SHY) in preventing recurrence of nephrolithiasis. Study Design: Open labeled, single arm, clinical trial. Materials and Methods: The study was conducted on 75 cases of uncomplicated nephrolithiasis (Hisat al Kuliya). The post-trial assessment was done on 49 cases after five years. Subsequent to written and informed consent, patients of All genders between 18-60 years with 6-8mm calculi were given SHY (5g twice daily orally for 8 weeks). Patients were followed up fortnightly, investigated at day 0, 15 and 60 and enquired about their diet and fluid intake. The data was analyzed on Tukey-Kramer multiple comparison test and paired t test. Results: Mean age of patients was 33.45±10.99 years CI (30.92-35.99). SHY reduced 24 hr calcium excretion highly significantly (p<0.0001). Calculus clearance rate was 64% and recurrence after five years was 29.16%. The drug was well tolerated. Conclusion: SHY probably corrects crystalloid colloidal imbalance or the oxalate metabolism and/or renal functions; thus, preventing recurrence. However, the exact mechanism of the drug needs to be studied.